Newsroom
1-3 of 3 items
- Press Release
04 July 25
CuraTeQ Biologics receives EC marketing authorization for Dazublys – Trastuzumab biosimilar
Read more - Press Release
26 April 25
CuraTeQ Biologics receives CHMP positive opinion for Dazublys – Trastuzumab biosimilar
Read more - Press Release
13 December 24
CuraTeQ Biologics receives CHMP positive opinion for Filgrastim biosimilar
Read more
1-3 of 3 items